Development of the next generation anti-HIV agents
update：2022-06-28
Features
HIV infection is one of most serious concern in infectious diseases. We will perform anti-HIV assays for unmet medical needs in control of HIV infections with established novel assays. We have developed reverse transcriptase inhibitor that has novel mechanism of inhibition, translocation-inhibition (J Biol Chem, 2009). Dr Kodama participated in the primary screening and development of a new HIV integrase inhibitor, elvitegravir (J Virol 2009), and a unique reverse transcriptase inhibitor, islatravir, which phase III clinical trials by the Merck & Co., Inc. will complete, soon. We have a representative resistant HIV strain-library for anti-HIV screening and several target oriented high through-put screening systems.Targeted Application(s)/Industry
We can establish high through-put screening for new targets, so please consult with us individually. We are open to joint development requiring BSL3/P3 experimental facilities and academic guidance including other microorganisms.Researchers
International Research Institute of Disaster Science
KODAMA Eiichi
, Professor
MD, PhD
Keywords
Related Information
2 Salie et al. Structural basis of HIV inhibition by translocation-defective RT inhibitor 4’-ethynyl-2-fluoro-2’-deoxyadenosine (EFdA). Proceedings of National Academy of Science of the United States of America 113:9274–9279, 2016
3 Watanabe et al. A novel peptide derived from the fusion protein heptad repeat inhibits replication of subacute sclerosing panencephalitis virus in vitro and in vivo. PLOS ONE 11: e0162823, 2016
4 Oe et al. Pyrimidine analogues as a new class of gram-positive antibiotics, mainly targeting thymineless-death related proteins. ACS Infectious Diseases 6:1490–1500, 2020
5 Tsukada et al. Synthetic biology-based construction of biological activity-related library of fungal decalin-containing diterpenoid pyrones. Nature Communications 11, Article number: 1830, 2020
6 Nakagawara et al. Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir. Antiviral Chemistry and Chemotherapy 28:1-5, 2020 doi:10.1177/2040206620921319
7 Ohata et al. Antiviral Activity and Resistance Profile of the Novel HIV-1 Non-Catalytic Site Integrase Inhibitor, JTP-0157602. Journal of Virology 96:e01843-21. doi: 10.1128/JVI.01843-21
8 Makino et al. Serine hydroxymethyltransferase as a potent target of antibacterial agents acting synergistically with one-carbon metabolism-related inhibitors. Communications Biology 2022 in printing
Prev
List
Next